| Title | Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China |
| Authors | Wang, Kaidi Xu, Li Yuan, Zhilan Yao, Ke Zhao, Junmei Xu, Liang Fang, Aiwu Zhang, Mingzhi Wu, Lingling Ji, Jian Hou, Jiamin Liu, Qing Sun, Xinghuai |
| Affiliation | Fudan Univ, Shanghai Med Coll, Eye ENT Hosp, Shanghai, Peoples R China. Fourth Peoples Hosp Shenyang, Dept Ophthalmol, Shenyang, Peoples R China. Peoples Hosp Jiangsu, Dept Ophthalmol, Nanjing, Jiangsu, Peoples R China. Zhejiang Univ, Coll Med, Affiliated Hosp 2, Eye Ctr, Hangzhou 310003, Zhejiang, Peoples R China. Shanxi Eye Hosp, Taiyuan, Peoples R China. Capital Univ Med Sci, Beijing Inst Ophthalmol, Beijing Tongren Hosp, Beijing, Peoples R China. Wenzhou Med Coll, Hosp Eye, Wenzhou, Peoples R China. Shantou Univ Shantou, Joint Shantou Int Eye Ctr, Shantou, Peoples R China. Chinese Univ Hong Kong, Shantou, Peoples R China. Peking Univ, Ctr Eye, Hosp 3, Beijing 100871, Peoples R China. Tianjin Med Univ, Ctr Eye, Tianjin, Peoples R China. Xiamen Univ, Eye Inst, Xiamen, Peoples R China. Xiamen Univ, Xiamen Eye Ctr, Xiamen, Peoples R China. Allergan Informat Consulting Shanghai Co Ltd, Shanghai, Peoples R China. Fudan Univ, Shanghai Med Coll, Eye ENT Hosp, Fenyang Rd 83, Shanghai, Peoples R China. |
| Keywords | Bimatoprost Glaucoma Ocular hypertension Intraocular pressure Conjunctival hyperemia PROSTAGLANDIN ANALOGS TRAVOPROST 0.004-PERCENT CLINICAL-TRIAL RISK-FACTORS LATANOPROST MULTICENTER PROGRESSION TOLERABILITY INTERVENTION METAANALYSIS |
| Issue Date | 2014 |
| Publisher | bmc ophthalmology |
| Citation | BMC OPHTHALMOLOGY.2014,14. |
| Abstract | Background: To report the clinical outcomes in Chinese patients with primary open-angle glaucoma and ocular hypertension treated with bimatoprost 0.03% therapy. Methods: Two hundred sixty-three Chinese patients with primary open-angle glaucoma and ocular hypertension who needed initial or additional intraocular pressure (IOP) lowering were recruited in this prospective, open-label, multicenter clinical study and were treated with bimatoprost 0.03%. Patients received bimatoprost 0.03% as initial, replacement or adjunctive IOP-lowering therapy, and follow-up visits were performed at week 1, and month 1 and 3 of the bimatoprost treatment. The efficacy outcome measure was the post-treatment IOP level. The safety outcome measures included the rate of medication-related symptoms, physical signs, reported adverse events, and the level of conjunctival hyperemia. Results: Among 240 patients who could be categorized by pre-existing therapies and the bimatoprost therapy regimen in the study, IOP values observed in all medication conditions showed significant IOP reduction at all study visits compared with baseline. At 3 months, 8.0 +/- 3.7 mmHg (32.0%) reduction in IOP was observed in treatment-naive patients after bimatoprost monotherapy; in the patients previously on various therapy regimens, 1.9 +/- 2.8 mmHg (9.5%) to 6.4 +/- 6.1 mmHg (24.8%) additional IOP lowering was achieved after switching to bimatoprost monotherapy or bimatoprost combination therapy. The most common adverse event was conjunctival hyperemia, mainly of trace and mild intensity. Conclusions: Our results show that bimatoprost 0.03% was effective in lowering IOP with favorable safety in Chinese primary open-angle glaucoma and ocular hypertension patients. |
| URI | http://hdl.handle.net/20.500.11897/215722 |
| ISSN | 1471-2415 |
| DOI | 10.1186/1471-2415-14-21 |
| Indexed | SCI(E) |
| Appears in Collections: | 第三医院 |
